In a revelation that suggests Fan was likely forced out amid an internal power struggle, the former science chief told Fierce Biotech he hasn't settled on his next gig. 2. Takeda's gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucks Takeda has signed another gene therapy deal with Evozyne. For an undisclosed "double-digit million" upfront payment, Evozyne will use its computational and machine learning platform to discover novel protein sequences for Takeda's gene therapies. The deal could be worth $400 million down the line. 3. Pfizer rolls out voluntary retirement scheme in India as it dives deeper into digital Pfizer is beefing up digital capabilities in India to cope with changes in how its customers and patients experience products and services. As a result, the company has rolled out a voluntary retirement scheme to field sales force there.